Atle Fund Management AB Has $2.21 Million Stock Holdings in NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS)

Atle Fund Management AB cut its holdings in shares of NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS - Free Report) by 22.4% during the 1st quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 107,783 shares of the company's stock after selling 31,200 shares during the quarter. NewAmsterdam Pharma makes up approximately 1.0% of Atle Fund Management AB's holdings, making the stock its 26th largest holding. Atle Fund Management AB owned about 0.10% of NewAmsterdam Pharma worth $2,206,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors also recently bought and sold shares of NAMS. GF Fund Management CO. LTD. bought a new stake in NewAmsterdam Pharma during the fourth quarter valued at $50,000. National Bank of Canada FI bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $51,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in shares of NewAmsterdam Pharma by 19.4% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 3,675 shares of the company's stock valued at $80,000 after purchasing an additional 596 shares during the last quarter. KLP Kapitalforvaltning AS bought a new position in shares of NewAmsterdam Pharma during the fourth quarter valued at approximately $154,000. Finally, Avanza Fonder AB bought a new position in shares of NewAmsterdam Pharma during the first quarter valued at approximately $127,000. 89.89% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling

In related news, Director James N. Topper bought 2,520 shares of NewAmsterdam Pharma stock in a transaction that occurred on Tuesday, June 24th. The stock was purchased at an average cost of $18.43 per share, for a total transaction of $46,443.60. Following the acquisition, the director owned 3,024,873 shares in the company, valued at $55,748,409.39. This trade represents a 0.08% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Douglas F. Kling sold 51,043 shares of the company's stock in a transaction on Wednesday, July 16th. The shares were sold at an average price of $21.10, for a total transaction of $1,077,007.30. Following the transaction, the chief operating officer owned 44,000 shares of the company's stock, valued at approximately $928,400. The trade was a 53.71% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders acquired 12,364 shares of company stock valued at $236,839 and sold 198,612 shares valued at $4,025,887. 20.84% of the stock is owned by insiders.

NewAmsterdam Pharma Trading Up 1.0%

Shares of NAMS traded up $0.22 during midday trading on Friday, hitting $22.20. The stock had a trading volume of 951,534 shares, compared to its average volume of 746,919. NewAmsterdam Pharma Company N.V. has a fifty-two week low of $14.06 and a fifty-two week high of $27.29. The business has a 50-day simple moving average of $19.35 and a two-hundred day simple moving average of $20.18. The firm has a market cap of $2.49 billion, a P/E ratio of -11.81 and a beta of -0.03.

NewAmsterdam Pharma (NASDAQ:NAMS - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.49) EPS for the quarter, missing the consensus estimate of ($0.45) by ($0.04). NewAmsterdam Pharma had a negative return on equity of 37.34% and a negative net margin of 397.45%. The business had revenue of $2.98 million during the quarter, compared to analyst estimates of $1.46 million. On average, analysts expect that NewAmsterdam Pharma Company N.V. will post -1.75 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts recently commented on NAMS shares. The Goldman Sachs Group initiated coverage on NewAmsterdam Pharma in a research note on Thursday. They set a "neutral" rating and a $27.00 price objective for the company. Wall Street Zen upgraded shares of NewAmsterdam Pharma from a "sell" rating to a "hold" rating in a research report on Saturday, July 5th. Stifel Nicolaus started coverage on shares of NewAmsterdam Pharma in a research report on Tuesday, June 10th. They issued a "buy" rating and a $44.00 target price for the company. Needham & Company LLC restated a "buy" rating and issued a $40.00 target price on shares of NewAmsterdam Pharma in a research report on Thursday, June 12th. Finally, Citigroup initiated coverage on shares of NewAmsterdam Pharma in a report on Tuesday, June 17th. They issued a "buy" rating and a $42.00 price objective for the company. Two analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $41.30.

NewAmsterdam Pharma Company Profile

NewAmsterdam Pharma Company N.V., a late-stage biopharmaceutical company, develops therapies to enhance patient care in populations with metabolic disease. It is developing obicetrapib, an oral low-dose cholesteryl ester transfer protein (CETP) inhibitor, that is in various clinical trials as a monotherapy and a combination therapy with ezetimibe for lowering LDL-C for cardiovascular diseases.